Biogen (BIIB) Stock Forecast, Price & News

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

26 equities research analysts have issued twelve-month target prices for Biogen's stock. Their BIIB share price forecasts range from $263.00 to $371.00. On average, they anticipate the company's share price to reach $328.92 in the next year. This suggests a possible upside of 9.6% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

Biogen's stock was trading at $276.92 at the start of the year. Since then, BIIB shares have increased by 8.4% and is now trading at $300.20.
View the best growth stocks for 2023 here.

Biogen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 30.4% from the April 30th total of 2,270,000 shares. Based on an average daily volume of 905,900 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the company's shares are sold short.
View Biogen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our BIIB earnings forecast.

Biogen Inc. (NASDAQ:BIIB) issued its earnings results on Tuesday, April, 25th. The biotechnology company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.25 by $0.15. The biotechnology company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 30.99% and a trailing twelve-month return on equity of 19.60%. The company's revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.62 EPS.
Read the conference call transcript.

ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), VanEck Biotech ETF (BBH), Horizon Kinetics Medical ETF (MEDX), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), iShares Neuroscience and Healthcare ETF (IBRN), Subversive Mental Health ETF (SANE), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

Biogen issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $15.00-$16.00 for the period, compared to the consensus estimate of $15.48. The company issued revenue guidance of -.

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.66%), State Street Corp (4.67%), Wellington Management Group LLP (3.77%), Geode Capital Management LLC (2.14%), Envestnet Asset Management Inc. (1.77%) and Price T Rowe Associates Inc. MD (1.44%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends.

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $300.20.

Biogen (NASDAQ:BIIB) has a market capitalization of $43.45 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $21.54 on an earnings per share basis.

The company employs 8,725 workers across the globe.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.